During the last session, Pfizer Inc. (NYSE:PFE)’s traded shares were 35.46 million, with the beta value of the company hitting 0.61. At the end of the trading day, the stock’s price was $27.22, reflecting an intraday loss of -1.20% or -$0.33. The 52-week high for the PFE share is $42.22, that puts it down -55.11 from that peak though still a striking 5.91% gain since the share price plummeted to a 52-week low of $25.61. The company’s market capitalization is $153.71B, and the average intraday trading volume over the past 10 days was 33.28 million shares, and the average trade volume was 43.15 million shares over the past three months.
Pfizer Inc. (NYSE:PFE) trade information
Pfizer Inc. (PFE) registered a -1.20% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -1.20% in intraday trading to $27.22, hitting a weekly high. The stock’s 5-day price performance is -1.34%, and it has moved by 5.14% in 30 days. Based on these gigs, the overall price performance for the year is -33.28%. The short interest in Pfizer Inc. (NYSE:PFE) is 71.65 million shares and it means that shorts have 1.5 day(s) to cover.
Pfizer Inc. (PFE) estimates and forecasts
Statistics show that Pfizer Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Pfizer Inc. (PFE) shares have gone down -19.80% during the last six months, with a year-to-date growth rate more than the industry average at 20.11% against 4.20. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -56.10% this quarter and then drop -31.30% in the quarter after that. In the rating firms’ projections, revenue will increase 2.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $14.2 billion as predicted by 13 analyst(s). Meanwhile, a consensus of 13 analyst(s) estimates revenue growth to $13.24 billion by the end of Jun 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $16.59 billion and $12.73 billion respectively. In this case, analysts expect current quarter sales to shrink by -14.40% and then jump by 4.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -27.43%. While earnings are projected to return 20.36% in 2024, the next five years will return -1.20% per annum.
PFE Dividends
Pfizer Inc. is due to release its next quarterly earnings between April 30 and May 06. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance. Investors should also take the other fundamental and operational aspects into account before investing in the stock. The forward dividend ratio for Pfizer Inc. is 1.65, with the dividend yield indicating at 6.06 percent, continuing the trend of increasing dividends in recent years.
Pfizer Inc. (NYSE:PFE)’s Major holders
Pfizer Inc. insiders own 0.05% of total outstanding shares while institutional holders control 69.94%, with the float percentage being 69.97%. Vanguard Group Inc is the largest shareholder of the company, while 3,665 institutions own stock in it. As of Jun 29, 2023, the company held over 508.09 million shares (or 9.00% of all shares), a total value of $18.64 billion in shares.
The next largest institutional holding, with 445.15 million shares, is of Blackrock Inc.’s that is approximately 7.88% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $16.33 billion.
Also, the Mutual Funds coming in first place with the largest holdings of Pfizer Inc. (PFE) shares are Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 176.05 million shares. This amounts to just over 3.12 percent of the company’s overall shares, with a $6.46 billion market value. The same data shows that the other fund manager holds slightly less at 134.41 million, or about 2.38% of the stock, which is worth about $4.93 billion.
